115 related articles for article (PubMed ID: 7640036)
1. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction.
Ajani JA; Roth JA; Putnam JB; Walsh G; Lynch PM; Roubein LD; Ryan MB; Natrajan G; Gould P
Eur J Cancer; 1995; 31A(5):665-70. PubMed ID: 7640036
[TBL] [Abstract][Full Text] [Related]
2. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.
Ajani JA; Mansfield PF; Lynch PM; Pisters PW; Feig B; Dumas P; Evans DB; Raijman I; Hargraves K; Curley S; Ota DM
J Clin Oncol; 1999 Aug; 17(8):2403-11. PubMed ID: 10561303
[TBL] [Abstract][Full Text] [Related]
3. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Geh JI; Glynne-Jones R; Kwok QS; Banerji U; Livingstone JI; Townsend ER; Harrison RA; Mitchell IC
Clin Oncol (R Coll Radiol); 2000; 12(3):182-7. PubMed ID: 10942336
[TBL] [Abstract][Full Text] [Related]
4. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
[TBL] [Abstract][Full Text] [Related]
5. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan B; McMurtrey M; Rich TA; Jackson DE; Abbruzzese JL; Levin B; DeCaro L; Mountain C
J Clin Oncol; 1990 Jul; 8(7):1231-8. PubMed ID: 2358838
[TBL] [Abstract][Full Text] [Related]
7. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
[TBL] [Abstract][Full Text] [Related]
8. Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction.
Stahl M; Vanhoefer U; Stuschke M; Walz MK; Müller C; Wilke H
Eur J Cancer; 1998 Apr; 34(5):668-73. PubMed ID: 9713272
[TBL] [Abstract][Full Text] [Related]
9. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Roth JA; Ryan MB; Putnam JB; Pazdur R; Levin B; Gutterman JU; McMurtrey M
J Clin Oncol; 1993 Jan; 11(1):22-8. PubMed ID: 8418237
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Kelsen D; Karpeh M; Schwartz G; Gerdes H; Lightdale C; Botet J; Lauers G; Klimstra D; Huang Y; Saltz L; Quan V; Brennan M
J Clin Oncol; 1996 Jun; 14(6):1818-28. PubMed ID: 8656250
[TBL] [Abstract][Full Text] [Related]
11. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Larsen AC; Holländer C; Duval L; Schønnemann K; Achiam M; Pfeiffer P; Yilmaz MK; Thorlacius-Ussing O; Bæksgaard L; Ladekarl M
Ann Surg Oncol; 2015 May; 22(5):1540-7. PubMed ID: 25348777
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
Melcher AA; Mort D; Maughan TS
Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350
[TBL] [Abstract][Full Text] [Related]
13. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
[TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
16. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.
Ajani JA; Ota DM; Jessup JM; Ames FC; McBride C; Boddie A; Levin B; Jackson DE; Roh M; Hohn D
Cancer; 1991 Oct; 68(7):1501-6. PubMed ID: 1893349
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Ychou M; Boige V; Pignon JP; Conroy T; Bouché O; Lebreton G; Ducourtieux M; Bedenne L; Fabre JM; Saint-Aubert B; Genève J; Lasser P; Rougier P
J Clin Oncol; 2011 May; 29(13):1715-21. PubMed ID: 21444866
[TBL] [Abstract][Full Text] [Related]
18. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus.
Ajani JA; Ryan B; Rich TA; McMurtrey M; Roth JA; DeCaro L; Levin B; Mountain C
Eur J Cancer; 1992; 28A(4-5):880-4. PubMed ID: 1524915
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
Samel S; Hofheinz R; Hundt A; Sturm J; Knoll MR; Wenz F; Queisser W; Post S
Onkologie; 2001 Jun; 24(3):278-82. PubMed ID: 11455222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
